Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extended-release guanfacine in adolescents with ADHD
2011-002221-21Phase 3
- Sponsor
- Takeda
- Start
- Aug 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in attention deficit hyperactivity disorder (ADHD) comparing Extended-release guanfacine hydrochloride with Placebo (2 arms). Primary endpoint: Change from baseline in ADHD-RS-IV total score at Week 13.
02
Drugs
guanfacine
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on 2011-002221-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-002221-21.